Compare Stocks

Date Range: 

 Kiniksa PharmaceuticalsMersana TherapeuticsStoke TherapeuticsOmerosPraxis Precision Medicines
SymbolNASDAQ:KNSANASDAQ:MRSNNASDAQ:STOKNASDAQ:OMERNASDAQ:PRAX
Price Information
Current Price$14.58$15.01$33.52$17.71$26.54
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.71.21.51.41.7
Analysis Score3.53.43.43.33.5
Community Score2.42.73.03.04.4
Dividend Score0.00.00.00.00.0
Ownership Score2.50.00.80.80.0
Earnings & Valuation Score0.00.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$37.00$26.17$64.33$23.00$60.33
% Upside from Price Target153.77% upside74.33% upside91.93% upside29.87% upside127.33% upside
Trade Information
Market Cap$998.23 million$1.06 billion$1.19 billion$1.11 billion$1.08 billion
Beta0.032.540.631.65N/A
Average Volume478,515947,931176,668697,662171,567
Sales & Book Value
Annual RevenueN/A$42.12 millionN/A$111.81 millionN/A
Price / SalesN/A24.61N/A9.87N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.10 per share$1.64 per share$6.86 per share($2.19) per shareN/A
Price / BookN/A9.15N/A-8.09N/A
Profitability
Net Income$-161,870,000.00$-28,210,000.00$-32,330,000.00$-84,490,000.00N/A
EPS($2.99)($0.65)($1.80)($0.96)N/A
Trailing P/E RatioN/AN/AN/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-8,772.91%N/A-134.59%N/A
Return on Equity (ROE)-53.65%-45.16%-22.93%N/AN/A
Return on Assets (ROA)-49.11%-37.53%-22.26%-59.49%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.02%N/AN/AN/A
Current Ratio15.20%13.05%29.02%4.11%N/A
Quick Ratio15.20%13.05%29.02%4.07%N/A
Ownership Information
Institutional Ownership Percentage42.00%N/AN/A56.63%N/A
Insider Ownership Percentage70.63%5.30%54.60%11.30%N/A
Miscellaneous
Employees1681107927767
Shares Outstanding68.23 million69.05 million36.70 million62.33 million38.63 million
Next Earnings Date7/29/2021 (Estimated)5/10/2021 (Confirmed)5/21/2021 (Estimated)5/10/2021 (Confirmed)6/16/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Praxis Precision Medicines (NASDAQ:PRAX) Sees Strong Trading VolumePraxis Precision Medicines (NASDAQ:PRAX) Sees Strong Trading Volume
americanbankingnews.com - May 7 at 11:54 AM
Should You Take Comfort From Insider Transactions At Praxis Precision Medicines, Inc. (NASDAQ:PRAX)?Should You Take Comfort From Insider Transactions At Praxis Precision Medicines, Inc. (NASDAQ:PRAX)?
nasdaq.com - May 3 at 12:46 PM
Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down to $32.22Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down to $32.22
americanbankingnews.com - May 3 at 12:06 PM
William Blair Initiates Coverage on Praxis Precision Medicines (NASDAQ:PRAX)William Blair Initiates Coverage on Praxis Precision Medicines (NASDAQ:PRAX)
americanbankingnews.com - May 3 at 10:10 AM
Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Metrics You Need to Know Right NowPraxis Precision Medicines, Inc. (NASDAQ:PRAX)Metrics You Need to Know Right Now
stocksregister.com - May 1 at 1:24 PM
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 11.2%Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 11.2%
americanbankingnews.com - April 30 at 11:39 AM
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEEPraxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
ca.finance.yahoo.com - April 30 at 9:58 AM
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEEPraxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
finance.yahoo.com - April 30 at 9:58 AM
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 5.3%Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 5.3%
americanbankingnews.com - April 29 at 2:54 PM
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.
finance.yahoo.com - April 29 at 12:53 PM
Praxis Precision Medicines (NASDAQ:PRAX) Sees Large Volume IncreasePraxis Precision Medicines (NASDAQ:PRAX) Sees Large Volume Increase
americanbankingnews.com - April 27 at 11:38 AM
Why Praxis Precision Medicines Stock is Up During Todays SessionWhy Praxis Precision Medicine's Stock is Up During Today's Session
benzinga.com - April 26 at 5:55 PM
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.7%Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.7%
americanbankingnews.com - April 23 at 1:36 PM
Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Up to $25.97Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Up to $25.97
americanbankingnews.com - April 22 at 11:34 AM
Praxis Precision Medicines (NASDAQ:PRAX) Trading 8.3% Higher Praxis Precision Medicines (NASDAQ:PRAX) Trading 8.3% Higher
americanbankingnews.com - April 21 at 1:38 PM
Affinivax Appoints Stuart Chaffee, PhD, as Chief Business OfficerAffinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer
apnews.com - April 20 at 8:56 AM
Praxis Precision Medicines, Inc. Common Stock (PRAX)Praxis Precision Medicines, Inc. Common Stock (PRAX)
nasdaq.com - April 20 at 12:21 AM
Heres Why Were Not Too Worried About Praxis Precision Medicines (NASDAQ:PRAX) Cash Burn SituationHere's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation
finance.yahoo.com - April 19 at 7:20 PM
Praxis Precision Medicines Inc (PRAX)Praxis Precision Medicines Inc (PRAX)
uk.investing.com - April 17 at 12:02 AM
Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of ...Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of ...
apnews.com - April 15 at 7:35 PM
Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.
finance.yahoo.com - April 15 at 7:35 PM
Praxis Precision Medicines (NASDAQ:PRAX) Trading 4.5% Higher Praxis Precision Medicines (NASDAQ:PRAX) Trading 4.5% Higher
americanbankingnews.com - April 15 at 11:37 AM
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Short Interest Up 129.1% in MarchPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Short Interest Up 129.1% in March
americanbankingnews.com - April 15 at 1:06 AM
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEEPraxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
finance.yahoo.com - April 14 at 1:23 PM
Praxis Precision Medicines to Present at Stifel’s 3rd Annual CNS DayPraxis Precision Medicines to Present at Stifel’s 3rd Annual CNS Day
finance.yahoo.com - March 24 at 10:27 AM
DateCompanyBrokerageAction
11/24/2020Kiniksa PharmaceuticalsEvercore ISIInitiated Coverage
6/30/2020Kiniksa PharmaceuticalsThe Goldman Sachs GroupBoost Price Target
6/29/2020Kiniksa PharmaceuticalsBank of AmericaBoost Price Target
6/29/2020Kiniksa PharmaceuticalsWedbushBoost Price Target
3/11/2020Kiniksa PharmaceuticalsJPMorgan Chase & Co.Boost Price Target
8/14/2019Kiniksa PharmaceuticalsJMP SecuritiesLower Price Target
3/11/2019Kiniksa PharmaceuticalsBarclaysInitiated Coverage
3/30/2021Mersana TherapeuticsCredit Suisse GroupInitiated Coverage
12/2/2020Mersana TherapeuticsStifel NicolausInitiated Coverage
11/9/2020Mersana TherapeuticsSVB LeerinkBoost Price Target
6/24/2020Mersana TherapeuticsBTIG ResearchBoost Price Target
6/23/2020Mersana TherapeuticsHC WainwrightReiterated Rating
5/28/2020Mersana TherapeuticsRobert W. BairdBoost Price Target
1/13/2020Mersana TherapeuticsCowenReiterated Rating
3/17/2021Stoke TherapeuticsCanaccord GenuityBoost Price Target
1/14/2021Stoke TherapeuticsNeedham & Company LLCBoost Price Target
10/23/2020Stoke TherapeuticsCantor FitzgeraldInitiated Coverage
2/1/2021OmerosUBS GroupInitiated Coverage
12/4/2020OmerosMaxim GroupBoost Price Target
5/3/2021Praxis Precision MedicinesWilliam BlairInitiated Coverage
11/10/2020Praxis Precision MedicinesPiper SandlerInitiated Coverage
(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.